FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | ...

Group 1 - The stock of Heptagon Pharmaceuticals-B (02142.HK) has increased by over 4%, currently up by 3.29%, trading at HKD 13.49 [1] - The trading volume reached HKD 52.54 million [1]

Core Viewpoint - The article highlights the successful launch of the AI-driven HCAb model by Heptares Therapeutics, which is expected to revolutionize the development of next-generation therapeutic antibodies and enhance drug discovery processes [1] Company Developments - Heptares Therapeutics' stock rose over 4%, currently trading at 13.49 HKD with a transaction volume of 52.54 million HKD [1] - The company hosted the "Zhi Yao He Po Hui Chuang Xing Chen" Global R&D Day in Shanghai on October 28, where it unveiled its first fully human AI HCAb model [1] Technology and Innovation - The AI HCAb model is based on Heptares' proprietary Harbour Mice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] - This platform establishes a closed-loop process that combines AI design, intelligent screening, and wet lab validation, differentiating it from traditional screening methods [1] Market Implications - The AI HCAb model is anticipated to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - Heptares aims to reshape the landscape of biopharmaceutical development by leveraging AI capabilities and HCAb technology to address unmet clinical needs through data-driven predictive processes [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has launched its first fully human AI HCAb model driven by the Hu-mAtrIx™ AI platform, aiming to revolutionize the development of biopharmaceuticals through advanced AI capabilities [1] Group 1: Company Developments - HAPO Pharmaceuticals experienced a stock increase of over 4%, with a current price of 13.49 HKD and a trading volume of 52.54 million HKD [1] - The company successfully held the "Zhiyao HAPO Huichuang Xingchen" global R&D day event in Shanghai on October 28, where the new AI-driven model was officially announced [1] - The AI HCAb model is based on proprietary Harbour Mice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] Group 2: Industry Implications - The AI HCAb model is expected to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - The platform aims to reshape the landscape of biopharmaceutical development by creating a closed-loop process that combines AI design, intelligent screening, and wet lab validation [1] - HAPO Pharmaceuticals is leveraging AI capabilities and HCAb technology to expedite the implementation of innovative therapies and identify unmet clinical needs through data-driven predictive processes [1]

Core Insights - Heptares Therapeutics recently held a global R&D day in Shanghai, where it officially launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ artificial intelligence platform [1] - The model is based on Heptares' proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, this platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1] Industry Developments - During the event, the AI + Biopharmaceutical Ecosystem Alliance was officially launched, with members including Foton Capital, Insilico Medicine, Molecular Heart, Aweilo Medical Technology, Innovent Biologics, Fenglin Group, Taimi Medical, Yilinyun, Deep Intelligence, and Heptares Therapeutics [1]

Core Insights - The article highlights the top short-selling stocks in the market, with Anta Sports-R and Great Wall Motors-R both having a short-selling ratio of 100.00% [1][2] - Alibaba-SW leads in short-selling amount at 1.343 billion, followed by Pop Mart at 1.242 billion and Tencent Holdings at 1.215 billion [1][2] Short-Selling Ratios - Anta Sports-R (82020) has a short-selling amount of 635,500 and a ratio of 100.00% with a deviation of 10.36% [2] - Great Wall Motors-R (82333) has a short-selling amount of 7,250 and a ratio of 100.00% with a deviation of 30.20% [2] - SenseTime-WR (80020) has a short-selling amount of 1,122,200 and a ratio of 97.63% with a deviation of 51.92% [2] - Lenovo Group-R (80992) has a short-selling amount of 2,438,200 and a ratio of 94.23% with a deviation of 34.69% [2] Short-Selling Amounts - Alibaba-SW (09988) has a short-selling amount of 1.343 billion with a ratio of 9.98% and a deviation of -6.17% [2] - Pop Mart (09992) has a short-selling amount of 1.242 billion with a ratio of 30.78% and a deviation of 9.42% [2] - Tencent Holdings (00700) has a short-selling amount of 1.215 billion with a ratio of 11.50% and a deviation of -4.97% [2] Short-Selling Deviation Values - SenseTime-WR (80020) has the highest deviation value at 51.92% [2] - HAPO Pharmaceutical-B (02142) has a short-selling amount of 15,513,500 with a deviation of 37.04% [2] - Lenovo Group-R (80992) has a deviation of 34.69% [2] - Great Wall Motors-R (82333) has a deviation of 30.20% [2]

Core Insights - The Chinese innovative pharmaceutical industry is transitioning into a new phase characterized by "in China, in Global," indicating a shift from merely serving local needs to integrating into the global ecosystem [1][7][10] - The surge in business development (BD) transactions has reignited investor interest, but concerns about undervaluing early-stage innovations persist [1][3][9] Group 1: Industry Development - The Chinese innovative drug sector has evolved from "in China, for Global" to "in China, in Global," reflecting a more integrated role in the global value chain [1][7] - The industry has seen a 400% increase in drug development activities over the past decade, surpassing international growth rates [7] - The emergence of a new BD transaction model, Co-Co, allows for shared responsibilities and profits between Chinese biotech firms and multinational corporations [4][5][10] Group 2: Business Development Transactions - Recent BD transactions have reached unprecedented amounts, with a notable deal between Innovent Biologics and Takeda Pharmaceuticals valued at up to $11.4 billion [3][4] - The Co-Co model represents a departure from traditional licensing agreements, enabling Chinese firms to retain more control and share in the commercialization process [4][5] - The number of BD transactions is increasing, indicating a growing acceptance of Chinese biotech capabilities in the global market [5][6] Group 3: Market Dynamics - Despite the increase in BD activity, the capital market's response has been lukewarm, with concerns about the sustainability of these transactions and the potential for future "washouts" [9][12] - The focus is shifting from individual "star pipelines" to platforms that demonstrate ongoing innovation capabilities, with AI integration becoming a standard expectation [12] - Multinational companies are increasingly establishing R&D centers in China, attracted by local scientific talent and technological advancements [10][11]

Core Insights - The report emphasizes the significant role of phosphoramidite monomers in the small nucleic acid industry chain, highlighting their impact on the development of small nucleic acid drugs, which are considered promising candidates for treating various diseases due to their unique molecular structures and therapeutic mechanisms [1][6][10] - The report predicts robust growth in the demand for phosphoramidite monomers, with multinational pharmaceutical companies likely to benefit from this trend, as the global nucleotide market is projected to reach USD 730 million in 2023, with China being the largest production market [10][11] Section Summaries Phosphoramidite Monomer's Role - Phosphoramidite monomers are crucial raw materials for synthesizing small nucleic acid drugs, enhancing their stability and biological activity, and driving innovation in drug development [6][9] - The solid-phase phosphoramidite method is the mainstream technique for synthesizing oligonucleotides, which are a major cost component in nucleic acid drug production [9] Market Dynamics - The report notes that 90% of global nucleotides are used for nucleic acid drug production, with only about 10% allocated to health foods and agriculture [10] - The small nucleic acid drug market is primarily dependent on major multinational pharmaceutical companies, indicating potential benefits for companies within their supply chains [11] Investment Recommendations - The report suggests focusing on innovative drug companies such as Furuya Co., OncoOne, and others, as well as raw material suppliers like WuXi AppTec and others, indicating a diverse range of investment opportunities in the sector [10]

Core Insights - The establishment of the Heptagon Pharmaceuticals-AstraZeneca Innovation Laboratory in Beijing marks a significant milestone in the collaboration between the two companies, enhancing their strategic partnership in drug development [1][2] - Heptagon Pharmaceuticals has formed partnerships with multiple multinational pharmaceutical companies, accumulating over $10 billion in total collaboration agreements [1] - The collaboration aims to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, with a focus on integrating AI in drug design and clinical development [2] Company Developments - Heptagon Pharmaceuticals has expanded its self-developed pipeline from 5 products to over 20, covering various therapeutic areas including oncology, inflammation, immune diseases, metabolic diseases, and central nervous system disorders [2] - The newly unveiled innovation laboratory is equipped with a comprehensive antibody drug innovation development platform and an AI wet-dry laboratory platform, which are set to accelerate the research and development process [1] Strategic Collaborations - The partnership includes a diversified collaboration model comprising research cooperation, equity investment, and the establishment of the Beijing Innovation Center, which injects new momentum into innovative drug development [1] - The collaboration with AstraZeneca is seen as a breakthrough in traditional Sino-foreign pharmaceutical partnerships, potentially leading to more innovative outcomes [2]

Core Viewpoint - The article discusses the internationalization of hard technology investments, highlighting the rebranding of Zijin Port Capital to Haiyuan Capital, which signifies a strategic shift towards a global perspective in innovation and investment [3][4]. Group 1: Internationalization of Hard Technology - By 2025, the focus of China's hard technology sector will shift from "internal competition" to "going global," with over 60 local R&D assets expected to be successfully authorized for international markets in 2024 [7]. - Deloitte's report indicates that 37% of large Chinese enterprises will have over 20% of their revenue from overseas by 2024, marking a transition from product export to brand and technology export [7]. - The internationalization of hard technology represents a fundamental shift in China's globalization model, moving from being a passive recipient of rules to an active shaper of global industry standards [7]. Group 2: Competitive Advantages in Hard Technology - China has made significant advancements in hard technology, particularly in sectors like renewable energy and artificial intelligence, establishing a robust supply chain and achieving world-leading technological capabilities [8]. - The comprehensive control over the entire supply chain in the renewable energy sector provides Chinese companies with unmatched cost advantages and scalability, essential for competing in the global market [8]. Group 3: Haiyuan Capital's Role - Haiyuan Capital's portfolio includes leading companies in the internationalization of hard technology, such as Jieput, which has subsidiaries in Japan, the US, and Singapore, and Daxiang Shengkai, which utilizes deep learning for real-time voice extraction [10][11]. - The investment strategies of Haiyuan Capital include leveraging the Hong Kong Stock Exchange for global capital access, establishing direct sales channels, and forming partnerships with strategic investors to enhance international presence [14][15][16]. - Haiyuan Capital has built a unique global innovation ecosystem through collaborations with top universities and institutions worldwide, facilitating the incubation of high-quality projects [19][20][21]. Group 4: Future Outlook - Haiyuan Capital aims to integrate resources from the Hangzhou Bay and Guangdong-Hong Kong-Macao Greater Bay Area to connect Chinese innovation with global markets, positioning itself as a bridge for hard technology [22].